SEC Comment Letter for Lantern Pharma Inc. (LTRN) (CIK 0001763950) (LTRN) — Jul 7, 2021
Lantern Pharma Inc. (LTRN) (CIK 0001763950)
Date: July 7, 2021 · CIK: 0001763950 · Accession: 0000000000-21-008376
AI Filing Summary & Sentiment
File numbers found in text: 333-257643
Letter
United States securities and exchange commission logo July 7, 2021 Panna Sharma Chief Executive Officer Lantern Pharma Inc. 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 Re:Lantern Pharma Inc. Registration Statement on Form S-3 Filed July 2, 2021 File No. 333-257643 Dear Mr. Sharma: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue
Show Raw Text
United States securities and exchange commission logo
July 7, 2021
Panna Sharma
Chief Executive Officer
Lantern Pharma Inc.
1920 McKinney Avenue, 7th Floor
Dallas, Texas 75201
Re:Lantern Pharma Inc.
Registration Statement on Form S-3
Filed July 2, 2021
File No. 333-257643
Dear Mr. Sharma:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel K. Donahue